Elysian Trace LLC (a Florida limited liability company) owns intellectual property in the form of a patentable pharmaceutical formula that in theory would eliminate the weight gain side effect of current generation selective serotonin reuptake inhibitor ("SSRI") antidepressants. This group of antidepressants includes citalopram (Celexa), paroxetine (Paxil), fluoxetine (Prozac) and sertraline (Zoloft), among others.
A prominent Ph.D.researcher in Neuroscience, who is also a psychiatrist, advises us that we have "a solid scientific rationale," and that "it makes good sense to pursue our strategy." [Quoted with permission.] A representative of the University of Florida at Gainesville has advised us that the University is willing to conduct a clinical trial of our formula. The estimated cost of a full clinical trial that woul yield statistically meaningful results is approximately $2.5 to $3 million.
Prior to seeking that amount of funding, we would like to conduct a pilot study, a much smaller version of a full clinical trial that would yield at least some evidence of whether or not our formula is effective. The estimated cost of a pilot study is approximately $85,000.
We are unable to fund the pilot study on our own and would be very grateful for contributions. We will keep a registry of donors who would like to participate in the pilot study or full clinical trial.
search terms: antidepressants-weight-gain study current november 11, 2014